Search results
DAWN (Day One Biopharmaceuticals Inc) may reap gains as insiders became active recently – Knox Daily
Knox Daily· 4 days agoAs a result of the transaction, York Charles N II now holds 224,868 shares, worth roughly $2.87 million. Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating ...
ArriVent partners Alphamab to develop ADCs for cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe partnership will...identifying and developing potential first and best-in-class product...
Investment Research Library
Morningstar· 6 days agoMorningstar's investment research library contains in-depth insights from hundreds of global analysts on thousands of stocks, funds, bonds, and more.
23andMe reports positive phase 2 data for cancer drug By Investing.com
Investing.com· 6 days agoThe data was presented at the American Society of Clinical Oncology Annual Meeting, which took place...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 5 days agoLabWare Continues to Provide Leadership Through Strategic Partnerships and Innovation in Ireland's BioPharma Sector PR Newswire WILMINGTON, Del., June 4, 2024 WILMINGTON, Del., June 4, 2024 /PRNewswire/ -- LabWare, a global leader in Laboratory
Biopower Player: Arie Belldegrun
Los Angeles Business Journal· 6 days agoArie Belldegrun used proceeds from biotech company sales to set up Bellco Capital, which has emerged as the center of a biotech funding and real estate...
Can Chemo Benefit Older Patients With Pancreatic Cancer?
Medscape· 2 days agoBetter tools are needed to identify vulnerable older patients with metastatic pancreatic cancer who...
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings
Benzinga· 5 days agoGC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) on June 7-8th at Waltham, Massachusetts as a sponsor to ...
Miller: Let’s make the next biotech revolution an American one
telegraphherald.com· 6 days agoOver the years, I have had a front-row seat at the biotech revolution. As a grad student, I did ...
Arrivent Biopharma enters into cancer drug development collaboration valued at up to $615M -...
The Business Journals· 3 days agoArriVent Biopharma has made a deal with a Chinese firm on a drug development collaboration...